Anne Lanner - Hansa Biopharma VP Officer

HNSA Stock

SEK 31.00 0.50 1.59%

Insider

Anne Lanner is VP Officer of Hansa Biopharma AB

Age	54
Phone	46 46 16 56 70
Web	https://www.hansabiopharma.com

Hansa Biopharma Management Efficiency

The company has return on total asset (ROA) of (0.2718) % which means that it has lost $0.2718 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8941) %, meaning that it generated substantial loss on money invested by shareholders. Hansa Biopharma's management efficiency ratios could be used to measure how well Hansa Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Hansa Biopharma to Peers

Predict price of Hansa Biopharma

Hansa Biopharma AB has accumulated 783.93 M in total debt with debt to equity ratio (D/E) of 1.6, which is about average as compared to similar companies. Hansa Biopharma AB has a current ratio of 15.14, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Hansa Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Hansa Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hansa Biopharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hansa to invest in growth at high rates of return. When we think about Hansa Biopharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Peter Nygren	Oncopeptides AB	64
	Danilo Verge	Zealand Pharma AS	N/A
	Bent MSc	ExpreS2ion Biotech Holding	N/A
	Christina Bredal	Zealand Pharma AS	38
	Jakob Lic	Oncopeptides AB	51
	Pr MD	Oncopeptides AB	N/A
	Ingrid Teige	BioInvent International AB	N/A
	Henriette Wennicke	Zealand Pharma AS	N/A
	Mattis Ranthe	ExpreS2ion Biotech Holding	N/A
	Ivan Moller	Zealand Pharma AS	51
	Hanne Bak	Zealand Pharma AS	70
	Max Sogaard	ExpreS2ion Biotech Holding	N/A
	MSc MD	Oncopeptides AB	N/A
	Mads Kronborg	Zealand Pharma AS	N/A
	MSc MSc	Oncopeptides AB	53
	Adam MD	Zealand Pharma AS	49
	Mette Thorn	ExpreS2ion Biotech Holding	N/A
	Lani Morvan	Zealand Pharma AS	N/A
	Lars Petersen	ExpreS2ion Biotech Holding	N/A
	Ravinder Chahil	Zealand Pharma AS	N/A
	Keith Alexander	ExpreS2ion Biotech Holding	N/A

Hansa Biopharma AB , a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. Hansa Biopharma AB was founded in 2001 and is headquartered in Lund, Sweden. Hansa Biopharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 60 people. Hansa Biopharma AB (HNSA) is traded on Stockholm Exchange in Sweden and employs 150 people.

Management Performance

	Return On Equity	-0.89
	Return On Asset	-0.27

Hansa Biopharma AB Leadership Team

Elected by the shareholders, the Hansa Biopharma's board of directors comprises two types of representatives: Hansa Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hansa. The board's role is to monitor Hansa Biopharma's management team and ensure that shareholders' interests are well served. Hansa Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hansa Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Henk Troostwijk, Vice President Commercial Operations
	Klaus Sindahl, Head Relations
	Sren MSc, Pres CEO
	Donato Spota, CFO VP
	Christian Kjellman, Senior Vice President Research and Development
	Lena Winstedt, Vice President Project Management
	Katja Margell, Head Communications
	EvaMaria Joed, Vice President Finance & Administration
	Anne Lanner, VP Officer
	Emanuel Bjrne, VP Devel

Hansa Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hansa Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.89
	Return On Asset	-0.27
	Operating Margin	(3.80) %
	Current Valuation	2.17 B
	Shares Outstanding	52.44 M
	Shares Owned By Insiders	7.37 %
	Shares Owned By Institutions	41.33 %
	Price To Book	7.52 X
	Price To Sales	17.67 X
	Revenue	154.53 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Hansa Stock Analysis

When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC